Atossa Therapeutics, Inc.'s SEC filings document a clinical-stage biopharmaceutical issuer focused on (Z)-endoxifen development in oncology and rare disease settings. Its reports include financial-result 8-Ks, corporate updates, Regulation FD communications, and disclosures tied to research and development spending for its lead product candidate.
The filing record also covers governance and capital-structure matters, including annual meeting votes, director elections, auditor ratification, executive-compensation votes, charter-authority proposals, Form S-3 and at-the-market offering disclosures, Nasdaq listing compliance, and material events involving Endoxifen-related intellectual property proceedings and settlement agreements.
Finn Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics director Jonathan Finn received an equity grant of 10,000 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is compensation-related, not an open-market purchase. After the grant, Finn directly holds 11,666 shares. According to the footnote, each RSU represents a contingent right to receive one share of Common Stock, and the RSUs shall vest on the first anniversary of May 12, 2026.
Galli Stephen J reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Stephen J. Galli received an award of 10,000 shares of Common Stock in the form of restricted stock units (RSUs) on May 12, 2026. After this grant, he holds 10,006 shares directly. Each RSU represents a contingent right to receive one share of Common Stock and will vest on the first anniversary of May 12, 2026.
Cigler Tessa reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Tessa Cigler reported an equity award of 10,000 shares of Common Stock on May 12, 2026. The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of Common Stock.
The RSUs vest on the first anniversary of May 12, 2026, meaning they become deliverable as shares after that date if vesting conditions are satisfied. Following this grant, Cigler is shown as directly holding 10,000 shares of Common Stock.
Atossa Therapeutics reported a larger net loss for the first quarter of 2026 as it invested more heavily in its (Z)-endoxifen programs in oncology and rare diseases. Net loss was $9.6 million, compared with $6.7 million a year earlier, with net loss per share widening to $1.11 from $0.78. Total operating expenses rose to $9.9 million, driven by higher clinical trial spending and legal costs tied to patent litigation and intellectual property work. Cash and cash equivalents were $31.7 million as of March 31, 2026, with no debt reported. During the quarter, Atossa secured FDA Orphan Drug and Rare Pediatric Disease designations for (Z)-endoxifen in Duchenne Muscular Dystrophy and an additional Rare Pediatric Disease designation in McCune-Albright Syndrome, while highlighting encouraging preclinical data in dystrophic mouse models and expanding its clinical leadership team.
Atossa Therapeutics, Inc. reported a larger net loss of $9.6M for the quarter ended March 31, 2026, with no revenue as it remains a clinical-stage company focused on (Z)-endoxifen programs in oncology and rare diseases. Operating expenses rose to $9.9M, driven mainly by higher clinical trial spending and legal fees tied to patent matters. Cash, cash equivalents and restricted cash fell to $31.8M, and management disclosed working capital of $29.2M and ongoing negative cash flows, stating that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Atossa put in place a new at-the-market equity program of up to $50M, effected a 1-for-15 reverse stock split, and highlighted FDA Rare Pediatric Disease and orphan designations for (Z)-endoxifen in Duchenne muscular dystrophy and McCune‑Albright Syndrome.
Atossa Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. As of the March 19, 2026 record date, 8,611,361 shares of common stock were entitled to vote. Stockholders elected three Class II directors and ratified Ernst & Young LLP as independent registered public accounting firm.
Stockholders also approved an amendment to the Amended and Restated Certificate of Incorporation authorizing a reverse stock split at a ratio from 2:1 to 20:1, if the board determines it is necessary or appropriate. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Atossa Therapeutics, Inc. entered into a Settlement Agreement with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc. to resolve patent disputes over Endoxifen-related intellectual property, including pending challenges before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board.
The parties agreed to seek termination of the identified PTAB proceedings and, if any proceeding is not fully terminated, not to participate further in that proceeding or related appeals, subject to the agreement’s terms. They also exchanged mutual covenants not to challenge specified Endoxifen-related patents and applications, with limited exceptions.
The agreement preserves Atossa’s ability to continue developing and commercializing Z-endoxifen base in its principal focus areas of oncology, endocrine dysfunction disorders and muscular dystrophy-related diseases, and allocates certain other Endoxifen-related fields and formulations among the parties. Atossa expects its two issued “Methods for Making and Using Endoxifen” U.S. patents to remain issued and fully enforceable against other third parties, and believes the settlement reduces uncertainty around its patent portfolio and supports its strategic development plans.
QUAY STEVEN C reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. President & CEO Steven C. Quay received an equity grant of 65,000 restricted stock units of Common Stock. These RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026. Following the grant, he directly holds 88,038 shares of Common Stock and has indirect ownership of 1,483 shares through Ensisheim Partners, LLC, an entity he wholly owns with Dr. Shu-Chih Chen. The share counts have been adjusted to reflect a one-for-fifteen reverse stock split of Common Stock that occurred on February 2, 2026.
Daniel Mark James reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics’ Chief Financial Officer Daniel Mark James received a grant of 63,000 restricted stock units of common stock. The award was granted at no cash cost to him and brings his reported direct holdings to 63,000 shares-equivalent.
The RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026, meaning the award is structured to retain and incentivize the CFO over multiple years.